🟠 Moderate Evidence
Alternate-day iron supplementation achieves significantly higher absorption rates than daily dosing, according to research from the University of Zurich and colleagues. When iron-depleted women took 60 mg ferrous sulfate on alternate days rather than consecutively, they absorbed 21.8% of each dose compared to 16.3% with daily dosing, with cumulative absorption reaching 175 mg versus 131 mg over the same treatment period, published in The Lancet Haematology (2017).
Key takeaways
- Alternate-day dosing of 60 mg ferrous sulfate achieves 21.8% absorption per dose versus 16.3% for daily consecutive dosing
- Total iron absorption over treatment was 175 mg on alternate days compared to 131 mg with daily dosing—a 34% absolute gain
- Even in iron-deficiency anemia where the body suppresses hepcidin, alternate-day absorption remains 40–50% higher than daily dosing
- Effect demonstrated in women only; efficacy in men and with other iron formulations remains untested
Study at a Glance
| Source | The Lancet Haematology |
| Study type | Randomised controlled trial (iron absorption cohort) |
| Sample size | N = 40 iron-depleted (non-anaemic) women |
| Population | Women with iron depletion, normal haemoglobin |
| Country | Switzerland |
Iron absorption efficiency: alternate-day versus daily dosing
Fractional absorption per dose and cumulative iron absorbed in women receiving 60 mg ferrous sulfate
Source: Stoffel et al., The Lancet Haematology, 2017 | Georgian Medical Journal News
How hepcidin limits daily iron absorption
The mechanism behind these findings lies in the body’s iron-regulatory hormone, hepcidin. When a single dose of 60 mg or more of elemental iron enters the bloodstream, the liver responds by releasing hepcidin, which binds ferroportin—the only iron export channel on intestinal epithelial cells—and degrades it, according to research published in Blood (2015).
With ferroportin degraded, iron absorbed by the next dose accumulates inside the enterocyte and cannot reach the bloodstream. This regulatory shutdown persists for approximately 24 hours. By 48 hours, hepcidin levels decline and ferroportin is regenerated on the intestinal cell surface, restoring the iron transport pathway. This physiological feedback explains why spacing doses more widely—allowing hepcidin to clear—yields higher net absorption.
See our Clinical Updates for more on iron supplementation guidelines.
Even in iron-deficiency anaemia, alternate-day dosing wins
A follow-up trial in 2019 examined whether this effect would differ in a population with genuine iron-deficiency anaemia, where the body’s demand for red blood cell production naturally suppresses hepcidin levels. If hepcidin is already reduced by disease, daily supplementation might overcome the regulatory block. Instead, Stoffel and colleagues found that alternate-day absorption remained 40–50% higher than daily dosing even in anaemic women, published in Blood (2019).
This finding is clinically significant: even when the body is actively attempting to override its own hepcidin response—by suppressing the hormone to demand more iron—the 24-hour rebound still limits absorption from consecutive daily doses. Alternate-day spacing outperforms daily regimens across both iron-replete and iron-depleted physiology, suggesting a fundamental absorption advantage independent of baseline iron status.
More on iron metabolism and pharmaceutical considerations can be found in related coverage.
Limitations and unanswered questions
All published evidence on alternate-day versus daily iron dosing derives from studies using ferrous sulfate—a specific, highly absorbable iron salt—in female participants only. Whether the absorption advantage holds for other iron formulations (ferrous fumarate, ferrous gluconate, or newer iron compounds) remains unknown. Similarly, sex differences in hepcidin regulation and iron absorption kinetics may affect efficacy in men, but no male cohorts have been tested under comparable conditions.
The studies also enrolled women with either iron depletion (normal haemoglobin) or iron-deficiency anaemia—populations in whom hepcidin regulation is either intact or partially suppressed. Whether the findings apply to normal iron-replete individuals, post-menopausal women, or those with chronic disease and dysregulated hepcidin (such as inflammation-driven anaemia of chronic disease) is unknown. See our Data & Numbers section for epidemiological context on iron deficiency prevalence.
Alternate-day ferrous sulfate dosing achieves 21.8% fractional absorption per dose, compared to 16.3% with consecutive daily dosing—a clinically meaningful 34% relative improvement in total iron absorbed over the treatment period.
— Stoffel et al., University of Zurich, The Lancet Haematology (2017)
What this means
Frequently asked questions
Why does my body shut down iron absorption after I take a supplement?
When you absorb a large amount of iron (60 mg or more), your liver releases hepcidin, a hormone that disables ferroportin—the protein that carries iron from your intestinal cells into your bloodstream. This shutdown protects you from iron overload. The system resets after about 24–48 hours, which is why spacing doses wider apart allows better absorption of your next dose.
Does alternate-day dosing work if I have iron-deficiency anaemia?
Yes. Even though iron-deficiency anaemia naturally suppresses hepcidin (allowing your body to demand more iron), the regulatory rebound from your previous dose still limits absorption from consecutive daily supplements. Studies show alternate-day absorption remains 40–50% higher than daily dosing even in anaemic women, according to Blood (2019).
Will alternate-day dosing work with my iron supplement form?
The evidence is specific to ferrous sulfate. Whether alternate-day spacing improves absorption of other iron forms (ferrous fumarate, ferrous gluconate, or newer compounds) has not been tested. Discuss your specific iron supplement with your clinician to confirm whether alternate-day regimens are appropriate for your formulation.
As evidence on iron supplementation protocols continues to evolve, clinicians and patients benefit from understanding the mechanistic basis—hepcidin’s 24–48 hour feedback cycle—behind dosing strategies. The alternate-day approach represents a practical, physiologically grounded option that may improve both efficacy and tolerability in iron-deficient populations. Future research should expand testing across different iron salts, male cohorts, and diverse clinical populations to confirm generalisability.
Source: Stoffel et al., 2017, The Lancet Haematology
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
